China Healthcare Weekly Wrap (5-9 Oct)
Key news this week: 1) Arrivent's ph3 lung cancer study flop, 2) efgartigimod (argenx/ZLAB) discontinued in a ph3 study in Sjogren’s disease, 3)...
84 Views
Jacobio (1167.HK): CEO Meeting Takeaways and Pipeline Updates/Analysis
​Jacobio's pan-KRAS shows a differentiated safety profile, with global study update anticipated from partner AstraZeneca. Glecirasib is expected to...
127 Views
Primer: Shanghai Allist Pharmaceuticals (688578 CH) - Aug 2026
Dominant Player in a High-Growth Niche: Shanghai Allist is a rapidly growing Chinese biopharmaceutical company with a sharp focus on oncology,...
90 Views
A-Share Margin Trading Weekly (Oct 9th): ANHUI JIANGHUAI AUTOMOBILE, SHARETRONIC DATA TECHNOLOGY
We analyzed A-share margin trading positions report for the past week and highlighted ANHUI JIANGHUAI AUTOMOBILE (600418 CH), SHARETRONIC DATA...
96 Views
China Healthcare Weekly Wrap (10-14 Aug)
1) LEGN 2Q results: Cavykti QoQ growth; in vivo CAR-T updates in 2H; 2) Jacobio profit alert on license income: AZ (pan-KRAS) and Allist (KRAS G12C...
110 Views